Pravastatin in diabetes associated hypercholesterolemia

Acta Diabetologica

Volumn 34, Issue 4, 1997, Pages 294-300

  Rustemeijer, C ^a   Schouten, J A ^b   Janssens, E N W ^c   Spooren, P F M J ^d   Van Doormaal, J J ^e  

^a AMSTELLAND HOSPITAL   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Drechtsteden Ziekenhuis   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diabetes mellitus; Hypercholesterolemia; Pravastatin

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; TIME FACTORS;

EID: 0031434880     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050091     Document Type: Article

References (39)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3:463-524, 1987
2. Barrett-Connor E, Orchard T, Diabetes and heart disease. In: Diabetes in America: Diabetes Data Compiled 1984, Washington DC: National Diabetes Data Group, Department of Health and Human Services, pp 1-41, 1985
3. Howard BV, Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28:613-628, 1987
4. Kannel WB, Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 110:1100-1107, 1985
5. Ginsberg HN. Lipoprotein physiology in non-diabetic and diabetic states: relationship to atherosclerosis. Diabetes Care 14: 839-855, 1991
6. Taskinen MR, Hyperlipidemia in diabetes. Balliere Clin Endocrinol Metab 4:743-775, 1990
7. Garg A, Lipid-lowering therapy and macrovascular disease in diabetes mellitus. Diabetes [Suppl 2] 41:111-115, 1992
8. Steiner G, The dyslipoproteinemias of diabetes. Atherosclerosis [Suppl] 110:S27-S33, 1994
9. Kannel WB, Castelli WR, Gordon T, McNamara PM, Serum cholesterol, lipoprotein and the risk of coronary heart disease. The Framingham Study. Ann Int Med 74:1-12, 1971
10. Gouldbourt U, Holtzman E, Neufeld HN, Total and high density lipoprotein cholesterol in the serum and risk mortality: evidence of a threshold effect. BMJ 290:1239-1243, 1985
11. Rose G, Shipley M, Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. BMJ 290:306-307, 1985
12. Lipid Research Clinic Program, The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984
13. Frick MH, Elo O, Haapa K, Hemonen OP, Heinsalmi P, Helo P, Hutunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää, H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA, Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment changes in risk factors and incidence of coronary heart disease. J Engl J Med 317:1237-1245, 1987
14. Jukema JW, Bruschke AVG, Boven AJ van, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, Rappard FM van, Lie KI, Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderate elevated serum cholesterol levels. Circulation 91:2528-2540, 1995
15. Shepherd J, Cobbe SM, Ford I, Isless CG, Lorimer AR, McFarlane PW, McKillop JH, Packard CJ, Prevention of coronary heart disease in men with hypercholesterolemia. N Engl Med 333: 1301-1307, 1995
16. Grundy SM, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33, 1988
17. Garg A, Grundy SM, Treatment of dyslipidemia in non-insulin dependent diabetes mellitus with lovastatin. Am J Cardiol 62:447-497, 1988
18. Garg A, Grundy SM, Lovastatin for lowering cholesterol levels in non-insulin dependent diabetes mellitus. N Engl J Med 318: 81-86, 1988
19. Yoshino G, Kazumi T, Iwai M, Long-term treatment of hypercholesterolemic in non-insulin dependent diabetics (NIDDM) with pravastatin. Atherosclerosis 75:67-72, 1989
20. Owens D, Stinson J, Collins P, Johnson A, Tomkin GH, Improvement of the regulation of cellular cholesterolgenesis in diabetics: the effect of reduction of serum cholesterol by simvastatin. Diabetic Med 8:151-156, 1991
21. Zambon S, Lapolla A, Sartore G, Gherardingher A, Corlella A, Manrato E, Crepaldi G, Fedele D, Long-term treatment with simvastatin in hypercholesterolemic non-insulin dependent diabetic patients. Curr Ther Res 52:221-229, 1992
22. Cassader M, Ruiu G, Gambino R, Alemanno N, Veglia F, Pagano G, Hypercholesterolemia in non-insulin dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels. Atherosclerosis 99:47-53, 1993
23. Raskin P, Ganda AP, Schwartz AP, Willard D, Rosenstock J, Lodewick PA, Cressman MD, Philipson B, Weiner B, McGovern ME, Norton JM, Lucinotta GG, Behounek BD, Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med 99:362-369, 1995
24. American Diabetes Association, Nutritional recommendations and principles for individuals with diabetes mellites. Diabetes Care 13:18-25, 1990
25. Friedewald WT, Levy RI, Frederickson DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultra centrifuge. Clin Chem 18:499-502, 1971
26. Hanefeld M, Cardiovascular risk factors in non-insulin dependent diabetes mellitus. Cardiovasc Risk Factors 2:368-375, 1992
27. Valsania P, Zarich SW, Kowalchuk GJ, Kosinski E, Warram JH, Krolewski AS, Severity of coronary artery disease in young patients with insulin-dependent diabetes mellitus. Am Heart J 122:695-700, 1991
28. Assman G, Schulte H, Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. Am J Cardiol [Suppl H] 63:33H-37H, 1989
29. Stamler J, Wentworth D, Neaton JD, Is relationship between serum cholesterol and risk of primary death from coronary heart disease continuous and graded? Findings in 355 222 primary screenees in the Multiple Risk Factor Intervention trial (MRFIT). JAMA 256:2823-2828, 1986
30. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
31. Scandinavian Simvastatin Survival Study, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344: 1383-1389, 1994
32. Hunninghake DB, Melhes MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, Insull W Jr, Pan HY, Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Once-daily versus twice-daily dosing. Atherosclerosis 85:219-227, 1990
33. Jones PH, Farmer JA, Cressman MD, McKenny JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Colfer HT, Rackley CE, Sigmunc WR, Schiout RC, Arensberg D, McGovern ME, Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 14: 146-151, 1991
34. Kissebah AH, Alfarsi S, Evans DJ, Adams PW, Integraded regulation of very low density protein triglyceride and apolipoprotein-B kinetics in non-insulin dependent diabetes mellitus. Diabetes 31:217, 1983
35. Brown MS, Goldstein JL, Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest 72:743-747, 1983
36. Umeda F, Watanabe J, Inoue K, Hisatomi A, Mimura K, Yamauchi T, Sake Y, Kunisaki M, Tajiri Y, Nawata H, Effect of pravastatin on serumlipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus. Endocrinol Jpn 39:45-50, 1992
37. Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M, A multinational study of the effects of low-dose pravastatin in patients with non-insulin dependent diabetes mellitus and hypercholesterolemia. Clin Cardiol 17:558-562, 1994
38. Ingelfinger JA, Bennett PH, Liebow IM, Miller M, Coronary heart disease in the Pima Indians: electrocardiographic findings and postmortem evidence of myocardial infarction in a population with high prevalence of diabetes mellitus. Diabetes 25: 561-565, 1976
39. Diabetes Drafting Group, Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres: The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia [Suppl] 28:615-640, 1985